Get started
Author

Meindert Boysen

Observed names: M. Boysen, Meindert Boysen,, Meindert H. Boysen
ORCID: 0000-0002-8944-8703
Observed ORCID: 0000-0002-8944-8703
OpenAlex ID: A5022800194
Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force
2016 · Praveen Thokala, Nancy Devlin, et al. · Value in Health · 802
PDF
Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force
2016 · Kevin Marsh, Maarten IJzerman, et al. · Value in Health · 518
PDF
NICE’s approach to measuring value
2021 · Felix Greaves, Meindert Boysen · BMJ · 78
Lifecycle HTA: promising applications and a framework for implementation. An HTAi Global Policy Forum Task Force report
2024 · Franz B. Pichler, Meindert Boysen, et al. · International Journal of Technology Assessment in Health Care · 23
How should we assess the clinical and cost effectiveness of histology independent cancer drugs?
2020 · Sophie Cooper, Jacoline C Bouvy, et al. · BMJ · 22
Erlotinib for the treatment of non-small-cell lung cancer
2008 · Prashanth Kandaswamy, Meindert Boysen, et al. · The Lancet Oncology · 18
An operationalization framework for lifecycle health technology assessment: a Health Technology Assessment International Global Policy Forum Task Force report
2024 · Franz B. Pichler, Meindert Boysen, et al. · International Journal of Technology Assessment in Health Care · 14
Abstracts of papers and posters
1995 · C. C. M. Veninga, P. Denig, et al. · Pharmacy World & Science · 14
Around the Tables – Contextual Factors in Healthcare Coverage Decisions Across Western Europe
2020 · Tineke Kleinhout-Vliek, Antoinette de Bont, et al. · International Journal of Health Policy and Management · 12
PDF
Advancing the use of artificial intelligence in health technology assessment activities: insights and next steps from the 2025 HTAi Global Policy Forum
2026 · Rebecca Trowman, Meindert Boysen, et al. · International Journal of Technology Assessment in Health Care · 5
PDF
Pcp19 - an Updated Nice Position on the Eq-5d-5l Valuation Set
2018 · S. Cooper, J. Bouvy, et al. · Value in Health · 5
Lenalidomide for the treatment of relapsed multiple myeloma
2009 · Elangovan Gajraj, Helen Chung, et al. · The Lancet Oncology · 4
Contextual factors in value-based decision support to enhance health technologies adoption: the case of biosimilars
2025 · Maximilian Otte, Zoltán Kaló, et al. · Frontiers in Pharmacology · 2
PDF
Reflections on NICE’s Uptake of New Methods: Past, Present, and the 2020 Review
2020 · Meindert Boysen, Ian Watson · PharmacoEconomics · 1
Cancer Drugs Fund: the bigger picture
2016 · Carole M Longson, Linda J Landells, et al. · BMJ · 1
Developing evidence-based guidance for health technologies: the NICE experience
2009 · David Barnett,, Andrew Stevens,, et al. · Oxford University Press eBooks · 1
Reframing the value of reserve antibiotics: how ultra-orphan reimbursement pathways could offer fair and equitable access to new antibiotics
2026 · Jennifer Quinn, Jutta Amersdorffer, et al. · Health Policy OPEN
PDF
OP02 A Managed Access Approach To Appraising New Cancer Drugs In England
2017 · Linda Landells, Martyn Burke, et al. · International Journal of Technology Assessment in Health Care
PDF
Amending the Guide to Methods of Technology Appraisal at Nice to Incorporate two New Value Elements: Burden of Illness And Wider Societal Impact
2014 · H. Knight, M. Boysen, et al. · Value in Health
Works count: 19
Citation count: 1,520
H-index: 9
I10-index: 9
Year
Topic
Type